Loading…
ENvue Medical, Inc. is projected to decline to $0.4979 by 2027, a -6% move from its current price of $0.528. FEED is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $0.5016 | $0.5282 | $0.5564 | +0.05% |
| Jul 14 | $0.4911 | $0.5285 | $0.5687 | +0.09% |
| Jul 15 | $0.4833 | $0.5287 | $0.5784 | +0.14% |
| Jul 16 | $0.4769 | $0.529 | $0.5868 | +0.18% |
| Jul 17 | $0.4713 | $0.5292 | $0.5943 | +0.23% |
| Jul 18 | $0.4663 | $0.5294 | $0.6011 | +0.27% |
| Jul 19 | $0.4618 | $0.5297 | $0.6076 | +0.32% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $0.4618 | $0.5297 | $0.6076 | +0.32% |
| Week 2 | $0.4377 | $0.5314 | $0.6452 | +0.64% |
| Week 3 | $0.4204 | $0.5331 | $0.6761 | +0.96% |
| Week 4 | $0.4065 | $0.5348 | $0.7036 | +1.29% |
| Week 5 | $0.3948 | $0.5365 | $0.7291 | +1.61% |
| Week 6 | $0.3846 | $0.5382 | $0.7532 | +1.94% |
| Week 7 | $0.3756 | $0.54 | $0.7762 | +2.26% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
ENvue Medical, Inc. is a Healthcare company that focuses on non-invasive biological response-activating devices intended to target biofilm prevention, pain therapy, wound healing, and at-home administration without medical professional assistance. Its products include UroShield, an ultrasound-based device designed to prevent bacterial colonization and biofilm in urinary catheters, increase antibiotic efficacy, and decrease pain and discomfort associated with catheter use.
The portfolio also includes PainShield, a patch-based therapeutic ultrasound technology to treat pain, muscle spasm, and joint contractures, and WoundShield, a patch-based therapeutic ultrasound device to facilitate tissue regeneration and wound healing. The company sells its products directly to patients and through distributor agreements in the United States, Europe, Australia, Israel, New Zealand, and internationally. ENvue Medical, Inc.
was formerly NanoVibronix, Inc. and changed its name to ENvue Medical, Inc. in December 2025. It was incorporated in 2003 and is based in Tyler, Texas.
FEED is a healthcare stock currently trading at $0.5364 with a market cap of $3.27M and a rank of 5421. The near-term outlook reflects a cautious stance, while the longer horizon shows meaningful upside potential in the forecasted path from 2026 onward. The 30-day technical picture sits in neutral territory, with a price path that could drift within the observed range before a clearer trend develops.
A major floor 63.1% below — a decisive break under it would weaken the trend.
The nearest floor, 9.7% below — buyers have tended to step in here.
The nearest ceiling, 75.4% above — a clean break opens room to run.
A major ceiling 400.0% above — clearing it would confirm fresh momentum.
Key FEED support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of FEED market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $0.5138 | Buy | $0.5229 | Buy |
| MA 10 | $0.529 | Sell | $0.546 | Sell |
| MA 20 | $0.6247 | Sell | $0.6217 | Sell |
| MA 50 | $0.8649 | Sell | $0.8945 | Sell |
| MA 100 | $1.38 | Sell | $1.59 | Sell |
| MA 200 | $2.72 | Sell | $5.92 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 33.58 | Neutral |
| Stoch RSI (14) | 94.84 | Sell |
| CCI (20) | -62.87 | Neutral |
| Williams %R (14) | -77.13 | Info |
| MACD (12,26,9) | 0.01 | Buy |
| ROC (12) | -18.14 | Sell |
| Bollinger %B (20,2) | 0.30 | Neutral |
| Stochastic %K (14) | 22.87 | Neutral |
| TRIX (15) | -2.10 | Sell |
| Awesome (5,34) | -0.22 | Sell |
| Ultimate (7,14,28) | 44.34 | Neutral |
| Momentum (10) | -0.04 | Sell |
| Aroon Osc (25) | -68.00 | Sell |
| Hull MA (9) | 0.51 | Buy |
| ADX (14) | 39.36 | Sell |
| ATR (14) | 0.04 | Info |
The 30-day picture is NEUTRAL. The RSI(14) is 30, and the stock trades below the 50-day simple moving average at $0.8793 and well below the 200-day simple moving average at $2.76. Key support is at $0.477 and resistance at $0.926. The 30-day range spans from $0.3771 to $0.7631, indicating limited recent price movement within that band.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.477 | $0.528 | $0.8258 | 0% | Neutral | |
| $0.3632 | $0.4979 | $0.7373 | -6% | Neutral | |
| $0.4641 | $0.6745 | $1.06 | +28% | Bullish | |
| $0.5248 | $0.8018 | $1.33 | +52% | Bullish | |
| $0.5183 | $0.8287 | $1.42 | +57% | Bullish | |
| $0.4972 | $0.8293 | $1.47 | +57% | Bullish | |
| $0.3945 | $0.6851 | $1.26 | +30% | Bullish | |
| $0.3828 | $0.691 | $1.30 | +31% | Bullish | |
| $0.4062 | $0.7615 | $1.47 | +44% | Bullish | |
| $0.4546 | $0.8842 | $1.74 | +67% | Bullish | |
| $0.3853 | $0.8563 | $1.85 | +62% | Bullish | |
| $1.01 | $2.26 | $5.19 | +327% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $0.477 | $0.528 | $0.6664 | +0.00% |
| August 2026 | $0.4717 | $0.5707 | $0.7188 | +8.09% |
| September 2026 | $0.4488 | $0.5505 | $0.7073 | -3.55% |
| October 2026 | $0.4485 | $0.5566 | $0.7274 | +1.12% |
| November 2026 | $0.4856 | $0.6087 | $0.8066 | +9.36% |
| December 2026 | $0.4862 | $0.6152 | $0.8258 | +1.07% |
Click any year to see its month-by-month FEED forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
ENvue Medical, Inc.'s 2026 outlook centres on $0.528, within a $0.477 to $0.8258 range. That marks a 0% change versus current levels. A consolidation phase looks the most probable path here.
By 2027, FEED could reach as high as $0.7373, with a base case around $0.4979 and support toward $0.3632 — roughly -6% from $0.528. Price action looks broadly range-bound.
Expect FEED to range from $0.4641 to $1.06 through 2028. The $0.6745 average target implies a +28% move from current prices. That is up +35% on the projected 2027 average. Buyers look set to stay in control over this stretch.
The FEED price prediction for 2029 points to an average of $0.8018 (low $0.5248, high $1.33) — a potential gain of +52% on today's $0.528. Momentum favours further upside here.
In 2030, FEED is projected to trade between $0.5183 and $1.42, averaging $0.8287 — a potential gain of +57% from today's $0.528. That is up +3% on the projected 2029 average. Buyers look set to stay in control over this stretch.
ENvue Medical, Inc.'s 2031 outlook centres on $0.8293, within a $0.4972 to $1.47 range. That is up 0% on the projected 2030 average. That marks a +57% change versus current levels. Momentum favours further upside here.
By 2032, FEED could reach as high as $1.26, with a base case around $0.6851 and support toward $0.3945 — roughly +30% from $0.528. Buyers look set to stay in control over this stretch.
Expect FEED to range from $0.3828 to $1.30 through 2033. The $0.691 average target implies a +31% move from current prices. That is up +1% on the projected 2032 average. Momentum favours further upside here.
The FEED price prediction for 2034 points to an average of $0.7615 (low $0.4062, high $1.47) — a potential gain of +44% on today's $0.528. Buyers look set to stay in control over this stretch.
In 2035, FEED is projected to trade between $0.4546 and $1.74, averaging $0.8842 — a potential gain of +67% from today's $0.528. That is up +16% on the projected 2034 average. Momentum favours further upside here.
ENvue Medical, Inc.'s 2040 outlook centres on $0.8563, within a $0.3853 to $1.85 range. That is -3% versus the projected 2035 average. That marks a +62% change versus current levels. Buyers look set to stay in control over this stretch.
By 2050, FEED could reach as high as $5.19, with a base case around $2.26 and support toward $1.01 — roughly +327% from $0.528. Momentum favours further upside here.
Investing $1,000 in FEED today (≈ 1,893.939394 FEED) could be worth
$4,271.5
+$3,271.5 (+327%) by 2050 · US Dollar
Based on the average projected FEED price of $2.26 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in FEEDwould be worth at today's price.
$1,000 invested in FEED on Jul 10, 2025 (≈ 104.166663 FEED) would be worth
$55
-$945 (-94.5%) today · 0.05× · US Dollar
Based on a FEED entry price of $9.6 vs. today's $0.528.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $0.52 | $1,015.38 | +1.5% |
| 1 month ago | $0.853 | $618.99 | -38.1% |
| 3 months ago | $1.66 | $318.07 | -68.2% |
| 6 months ago | $2.28 | $231.58 | -76.8% |
| 1 year ago | $9.6 | $55 | -94.5% |
| All time (5.0y) ago | $1,760 | $0.3 | -100.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our FEED forecast.
Our base-case forecast reaches $1.10 around 2050.
Implied market cap at $1.10: $6.7M
The multi-year forecast shows bullish sentiment in several years with rising average prices, culminating in a 2050 average of $2.32 and a 331.7% ROI. Specifically, 2028-2031 show improving averages (2028 avg $0.6918; 2029 avg $0.8233; 2030 avg $0.8505; 2031 avg $0.8521) with strong upside implied by later years (2035 avg $0.9028; 2040 avg $0.8703; 2050 avg $2.32 and max $5.33, ROI 331.7). Near-term years include a dip in 2027 (avg $0.5032; ROI -6.2) and a return toward higher levels by 2028 and beyond.
The forecast also notes a 2040 max of $1.91 and a 2035 max of $1.80, illustrating a path with volatility in the intermediate term but substantial upside by 2050. Overall, the outlook is bullish over the long term, though it includes near-term downside risk as shown by the 2027 figures and a 100% annualized volatility backdrop.
Tap a question to reveal the answer.
2030 avg $0.8505; min $0.5257; max $1.48; roiPct 58.6; sentiment BULLISH.
The forecast shows bullish sentiment in many later years, with 2050 avg $2.32 and ROI 331.7%; but 2027 has ROI -6.2 and 2026 ROI 0, indicating mixed near-term risk.
Yes—forecasts show potential to exceed $1, with 2030 max $1.48 and 2029 max $1.37, and higher in later years (2035 max $1.80; 2040 max $1.91; 2050 max $5.33).
Current price is $0.5364 and market cap is $3.27M.
RSI(14) is 30 with NEUTRAL sentiment. SMA50 is $0.8793 and SMA200 is $2.76. Support is $0.477 and resistance is $0.926, with a 30-day range of $0.3771 to $0.7631.
ENvue Medical, Inc. Community Discussion
0Share your ENvue Medical, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.